{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/incontinence-urinary-in-women/prescribing-information/antimuscarinics/","result":{"pageContext":{"chapter":{"id":"3d2d4594-7f5e-5ad4-9537-22965cd3859f","slug":"antimuscarinics","fullItemName":"Antimuscarinics","depth":2,"htmlHeader":"<!-- begin field 3b396496-4a28-438a-9c3b-7027a8a0eb20 --><h2>Antimuscarinics</h2><!-- end field 3b396496-4a28-438a-9c3b-7027a8a0eb20 -->","summary":"","htmlStringContent":"<!-- begin item 4fa1511b-3d3e-4067-bdef-3c502e4afeb4 --><!-- end item 4fa1511b-3d3e-4067-bdef-3c502e4afeb4 -->","topic":{"id":"c16535c5-1fa2-5d4a-a89f-9863872fca0e","topicId":"9e411d60-4060-4d95-8511-0998688cea47","topicName":"Incontinence - urinary, in women","slug":"incontinence-urinary-in-women","lastRevised":"Last revised in October 2019","chapters":[{"id":"592d340e-2c89-5e8e-9781-8398ef51af2c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"93b3be44-57e0-59a2-b936-4b447f0b2961","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c15069c4-b8dd-5092-9861-e20a636b9367","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3dc5fefe-1cf0-54d7-92d3-e1c0c60c6fb9","slug":"changes","fullItemName":"Changes"},{"id":"fb9741e6-b4f0-5ec2-ada2-a14af327feed","slug":"update","fullItemName":"Update"}]},{"id":"1ae974b5-487a-5fdf-88b5-6d9ed1e83525","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"399a4681-e92c-5e84-a738-fded957e135f","slug":"goals","fullItemName":"Goals"},{"id":"6507910a-37cb-51a9-8d3d-b69725293a87","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"9cd9dcb7-4d7b-5d3b-aa75-6fb40bf5928b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f79e3765-8adb-5e3f-b68f-48aa4ddeb34b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e1ab1bca-96c7-5187-894e-1e1fe32f92d6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"97c63b91-f53e-5694-b807-0899dd34d53a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0c2e43fc-1afb-59f4-8819-0ff5edc09eeb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3ab1ad04-1d9d-52bc-b4c9-ad0787598df3","slug":"definition","fullItemName":"Definition"},{"id":"a9c53f9f-2962-5eb2-8cae-91fc90a5a1f4","slug":"causes-contributing-factors","fullItemName":"Causes and contributing factors"},{"id":"4bbda54d-1a4f-591c-8463-082fcdf61d7c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e79a0901-9992-5f45-8cf5-c15ce06b5deb","slug":"complications","fullItemName":"Complications"},{"id":"b70db9b0-ddc3-5b42-888e-7171189f4ee5","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a84e9562-3c9c-5c5e-8832-06e65a89aa2f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"49f48003-2f49-51d5-acfe-7ba0fcff8fae","slug":"assessment-overview","fullItemName":"Assessment overview"},{"id":"060afa31-1619-5a1a-a7e5-bcb583129aca","slug":"assessing-the-type-of-urinary-incontinence","fullItemName":"Assessing the type of urinary incontinence"},{"id":"9897aa86-8c09-5550-8496-da8cb12787bf","slug":"assessing-for-underlying-causes-contributing-factors","fullItemName":"Assessing for underlying causes and contributing factors"},{"id":"49079af0-34b2-5cab-9135-40f57ee1eea4","slug":"assessing-for-complications","fullItemName":"Assessing for complications"},{"id":"c9c5f464-0433-5027-a22c-8d2b8fb239bd","slug":"assessing-the-severity-of-urinary-incontinence","fullItemName":"Assessing the severity of urinary incontinence"}]},{"id":"a7454b90-f574-597a-b3ce-8f0b3967e058","fullItemName":"Management","slug":"management","subChapters":[{"id":"26043de5-bad9-57d7-abad-98942e3ed62c","slug":"managing-stress-incontinence","fullItemName":"Scenario: Managing stress incontinence"},{"id":"280a972f-ec97-53b4-ab56-b67df1df40d3","slug":"managing-urgency-incontinence","fullItemName":"Scenario: Managing urgency incontinence"},{"id":"dff61990-c7a9-5600-b15a-e9098f480b65","slug":"managing-mixed-urinary-incontinence","fullItemName":"Scenario: Managing mixed urinary incontinence"},{"id":"4e21298e-b75d-5104-9b4b-a9817cb8d9b6","slug":"managing-overflow-urinary-incontinence","fullItemName":"Scenario: Managing overflow urinary incontinence"},{"id":"d5ace44e-cc5a-5618-bb48-24058af84ec8","slug":"managing-a-urogenital-fistula","fullItemName":"Scenario: Managing a urogenital fistula"}]},{"id":"d814319d-0309-591f-aa84-5dfa4933d33b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3d2d4594-7f5e-5ad4-9537-22965cd3859f","slug":"antimuscarinics","fullItemName":"Antimuscarinics"},{"id":"c57e795e-2c4a-5f04-83ae-289890ef29ea","slug":"desmopressin","fullItemName":"Desmopressin"},{"id":"2bf52d86-2720-51b1-9411-89ebb7ff9b07","slug":"duloxetine","fullItemName":"Duloxetine"},{"id":"7f2a8cea-ac55-5ac4-a58a-52dbe5d19228","slug":"intravaginal-oestrogen","fullItemName":"Intravaginal oestrogen"},{"id":"2e7111be-d25f-52ec-9f6b-2aaea7583699","slug":"mirabegron","fullItemName":"Mirabegron"}]},{"id":"3ef95f2d-4da4-5002-9243-64779078fc11","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bdb709b8-1321-594d-b446-51244a4b8f41","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6ce87fd7-7343-5da1-b9a5-0035a5703c2c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3fe3b863-a1f0-5938-9f0d-bb718d670d28","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"947b96f3-7dc6-5136-96f6-431519b4646a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"16662eed-08e1-5333-85c0-65d2e4722f09","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"9c5908f0-10fa-5d1c-8762-8a682a1ee2c8","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"532bc548-9f39-5742-9a38-cb92893a8407","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d814319d-0309-591f-aa84-5dfa4933d33b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a6dcdb76-cf22-58cc-8b83-e906833b8642","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field 516d8d81-4962-4bb0-9a12-a75c0083826a --><h3>Who should not receive an antimuscarinic?</h3><!-- end field 516d8d81-4962-4bb0-9a12-a75c0083826a -->","summary":"","htmlStringContent":"<!-- begin item 6c569c73-05b2-40c8-b846-a75c00838278 --><!-- begin field 94a2e662-ac58-49a3-ba85-a75c0083826a --><ul><li><strong>Do not prescribe an antimuscarinic drug to people with </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]: <ul><li>Myasthenia gravis.</li><li>Significant bladder outflow obstruction or urinary retention.</li><li>Severe ulcerative colitis, toxic megacolon.</li><li>Gastrointestinal obstruction, intestinal atony, paralytic ileus, pyloric stenosis.</li></ul></li><li><strong>In addition:</strong><ul><li>Do not prescribe oxybutynin (immediate release) to older women who may be at higher risk of a sudden deterioration in their physical or mental health [<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">NICE, 2019</a>].</li></ul></li><li><strong>Prescribe antimuscarinic drugs with caution to people with </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]: <ul><li>Acute myocardial infarction, arrythmias (may worsen), cardiac insufficiency, cardiac surgery, congestive heart failure, coronary artery disease, conditions characterised by tachycardia.</li><li>Autonomic neuropathy.</li><li>Diarrhoea, gastro-oesophageal reflux disease or hiatus hernia with reflux oesophagitis.</li><li>Hypertension.</li><li>Hyperthyroidism.</li><li>Susceptibility to angle-closure glaucoma.</li><li>Pyrexia.</li><li>Ulcerative colitis.</li></ul></li></ul><!-- end field 94a2e662-ac58-49a3-ba85-a75c0083826a --><!-- end item 6c569c73-05b2-40c8-b846-a75c00838278 -->","subChapters":[]},{"id":"6570acb1-3910-5c8b-9c97-b4f3f7a237ec","slug":"initiation-titration","fullItemName":"Initiation and titration","depth":3,"htmlHeader":"<!-- begin field 69b2c3c6-7cf5-492d-a277-a75c00841556 --><h3>What dose of antimuscarinic should I prescribe?</h3><!-- end field 69b2c3c6-7cf5-492d-a277-a75c00841556 -->","summary":"","htmlStringContent":"<!-- begin item bb12c320-aae1-4acc-9da8-a75c00841588 --><!-- begin field 435022d1-b885-4d9f-a309-a75c00841556 --><p><strong>Table 1.</strong> Licensed doses of antimuscarinic drugs for urinary incontinence. </p><table><thead><tr><th scope=\"col\">Antimuscarinic preparations</th><th scope=\"col\">Dose</th></tr></thead><tbody><tr><td>Oxybutynin immediate-release tablets (2.5 mg, 3 mg, and 5 mg)</td><td>5 mg two or three times a day, increasing to a maximum of 5 mg four times a day. In elderly women, a starting dose of 2.5 mg or 3 mg twice a day is recommended. Oxybutynin (immediate release) should not be given to older women who may be at higher risk of a sudden deterioration in their physical or mental health.</td></tr><tr><td>Oxybutynin prolonged-release tablets (Lyrinel XL<sup>®</sup>,5 mg and 10 mg)</td><td>5 mg daily, increasing to 10 mg daily after 7 days if necessary. Total daily dose should not exceed 20 mg. There should be an interval of at least 7 days between any dose changes.</td></tr><tr><td>Oxybutynin transdermal patch (Kentera<sup>®</sup>, releasing 3.9 mg of oxybutynin per 24 hours)</td><td>One 3.9 mg transdermal patch applied twice weekly (every 3 to 4 days).</td></tr><tr><td>Darifenacin prolonged-release tablets (Emselex<sup>®</sup>, 7.5 mg and 15 mg)</td><td>7.5 mg daily, increasing to 15 mg daily after 2 weeks if necessary.</td></tr><tr><td>Fesoterodine prolonged-release tablets (Toviaz<sup>®</sup>, 4 mg and 8 mg)</td><td>4 mg daily, increasing to 8 mg daily if necessary.</td></tr><tr><td>Propiverine hydrochloride tablets (Detrunorm<sup>® </sup>15 mg)</td><td>15 mg once or twice a day, increased if necessary to a maximum of 15 mg 3 times a day. Maximum dose 30 mg daily if eGFR† is less than 30 mL/minute/1.73 m<sup>2</sup>. </td></tr><tr><td>Propiverine hydrochloride capsules modified release (Detrunorm<sup>®</sup> XL 30 mg)</td><td>30 mg once daily. Maximum dose 30 mg daily if eGFR† is less than 30 mL/minute/1.73 m<sup>2</sup>. </td></tr><tr><td>Solifenacin immediate-release tablets (Vesicare<sup>®</sup>, 5 mg and 10 mg)</td><td>5 mg daily, increasing to 10 mg daily if necessary.<br>For people with severe renal impairment (creatinine clearance 30 mL/min or less), moderate hepatic impairment (Child–Pugh score of 7–9), and if treated with a potent inhibitor of CYP 3A4 (such as ketoconazole, itraconazole, nelfinavir, and ritonavir): do not exceed 5 mg daily.</td></tr><tr><td>Tolterodine immediate-release tablets (Detrusitol<sup>®</sup>, 1 mg and 2 mg)</td><td>2 mg twice a day. Reduce to 1 mg twice a day if adverse effects are troublesome.<br>For people with impaired liver function or severe renal impairment (eGFR† 30 mL/min/1.73m<sup>2</sup> or less) prescribe 1 mg twice a day.</td></tr><tr><td>Tolterodine prolonged-release capsules (Detrusitol XL<sup>®</sup> 4 mg)</td><td><p>4 mg daily.<br>In people with impaired liver function the recommended dose is 2 mg once daily. </p><p>This formulation is not suitable for people with severe renal impairment (eGFR† less than 30 mL/minute/1.73m<sup>2</sup>) and should be avoided.</p></td></tr><tr><td>Trospium chloride tablets (20 mg)</td><td>20 mg twice daily. Reduce dose to 20 mg once daily or 20 mg on alternate days if eGFR† is 10–30 mL/minute/1.73 m<sup>2</sup>. Avoid in severe hepatic impairment.</td></tr><tr><td>Trospium chloride prolonged-release capsule (Regurin XL<sup>®</sup> 60 mg)</td><td>60 mg once daily. This formulation is not suitable for people with renal impairment or severe hepatic impairment. </td></tr><tr><td colspan=\"2\">† estimated glomerular filtration rate</td></tr><tr><td colspan=\"2\"><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI Medicines Compendium, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">NICE, 2019</a>]</p></td></tr></tbody></table><!-- end field 435022d1-b885-4d9f-a309-a75c00841556 --><!-- end item bb12c320-aae1-4acc-9da8-a75c00841588 -->","subChapters":[]},{"id":"5ab94df3-28da-5eb9-8380-05e073f30915","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 7bf00537-95fc-40d8-9ef3-755e7fa7e599 --><h3>What adverse effects of antimuscarinics should I be aware of?</h3><!-- end field 7bf00537-95fc-40d8-9ef3-755e7fa7e599 -->","summary":"","htmlStringContent":"<!-- begin item 8a68e359-dc2b-45ed-b973-9a7aaf7b7120 --><!-- begin field 41d367a1-0375-4ae6-a46a-6fc981fe2977 --><ul><li><strong>Common adverse effects of antimuscarinic drugs include</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]: <ul><li>Dry mouth.</li><li>Constipation.</li><li>Dizziness.</li><li>Drowsiness.</li><li>Headache.</li><li>Nausea, vomiting, dyspepsia.</li><li>Palpitations, tachycardia.</li><li>Urinary disorders.</li><li>Vision disorders.</li><li>Skin reactions, flushing.</li></ul></li><li><strong>More rarely encountered adverse effects</strong> include angioedema or confusion (more common in older people) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>] .</li></ul><!-- end field 41d367a1-0375-4ae6-a46a-6fc981fe2977 --><!-- end item 8a68e359-dc2b-45ed-b973-9a7aaf7b7120 -->","subChapters":[]},{"id":"dd23d897-40a1-526f-b55b-3b6776ef57b5","slug":"interactions","fullItemName":"Interactions","depth":3,"htmlHeader":"<!-- begin field 841f36fd-a915-4a5a-bc9e-643d0d876107 --><h3>Interactions</h3><!-- end field 841f36fd-a915-4a5a-bc9e-643d0d876107 -->","summary":"","htmlStringContent":"<!-- begin item 2fac1ec4-4430-4751-8503-80607c31593e --><!-- begin field 15dea570-788c-4bbf-9b0d-7f049cf9da94 --><ul><li>For information on drug interactions for individual antimuscarinic drugs, see the manufacturers' Summaries of Product Characteristics (<a data-hyperlink-id=\"85d2b8b2-f73e-47da-abb4-a98f018419d2\" href=\"http://www.medicines.org.uk/\">www.medicines.org.uk</a>) or the <a data-hyperlink-id=\"dc0bc1ed-5d9a-4faf-a578-aade015884cc\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a>.</li></ul><!-- end field 15dea570-788c-4bbf-9b0d-7f049cf9da94 --><!-- end item 2fac1ec4-4430-4751-8503-80607c31593e -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}